Could a daily walk tame Immunotherapy's harsh side effects?

NCT ID NCT06627595

Recruiting now Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study explores whether being physically active can help melanoma patients avoid or lessen the immune-related side effects of immunotherapy drugs like pembrolizumab and nivolumab. Researchers will track the activity levels of 160 adults starting immunotherapy and monitor them for six months to see who develops toxicities. If a link is found, it could pave the way for exercise programs as a standard part of cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: physical activity (adapted physical activity sessions and self-reported activity levels)
What this could lead to: If physical activity is linked to fewer immunotherapy side effects, it could become a standard supportive care option for melanoma patients.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may show no clear link, or the benefit may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOTOXICITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma Motor Activity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOTOXICITY MELANOMA

Contacts and locations

Locations

CHU de Montpellier
RECRUITING

Montpellier, France
Institut du Cancer de Montpellier (ICM)
NOT_YET_RECRUITING

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.